Tokuyasu Naruo, Amisaki Masataka, Hanaki Takehiko, Murakami Yuki, Morimoto Masaki, Uchinaka Ei, Yagyu Takuki, Goto Keisuke, Matsunaga Tomoyuki, Yamamoto Manabu, Takano Shuichi, Sakamoto Teruhisa, Honjo Soichiro, Hasegawa Toshimichi, Fujiwara Yoshiyuki
Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago 683-8504, Japan.
Yonago Acta Med. 2021 Apr 15;64(2):168-175. doi: 10.33160/yam.2021.05.007. eCollection 2021 May.
As antithrombin III (AT-III) is produced in the hepatocytes, its serum activity decreases at the time of liver failure, in addition to ischemia reperfusion injury, vascular endothelial dysfunction, and disseminated intravascular coagulation (DIC). Here, we examined whether the serum AT-III value after hepatectomy could be a prognostic factor for hepatocellular carcinoma (HCC).
Of 141 patients who underwent hepatectomy for HCC, data for 101 patients in whom serum AT-III activity was measured on the first postoperative day were extracted. Patients with serum AT-III activity > 50% and ≤ 50% were assigned to high value (72 cases) and low value (29 cases) groups, respectively. We examined the clinical and prognostic differences between these two groups.
The average age of enrolled patients (83 men and 18 women) was 68.0 years. The 5-year overall survival rate was 88% and 60% in the high and low value groups, respectively ( < 0.01). Furthermore, the 2-year relapse-free survival rate was 71% and 54% in the high and low value groups, respectively ( = 0.03).
This is the first study to demonstrate that serum AT-III levels on the first postoperative day may serve as a prognostic factor in HCC patients.
由于抗凝血酶III(AT-III)由肝细胞产生,除了缺血再灌注损伤、血管内皮功能障碍和弥散性血管内凝血(DIC)外,在肝衰竭时其血清活性也会降低。在此,我们研究了肝切除术后血清AT-III值是否可作为肝细胞癌(HCC)的预后因素。
在141例行HCC肝切除术的患者中,提取了101例术后第一天测定血清AT-III活性患者的数据。血清AT-III活性>50%和≤50%的患者分别被分为高值组(72例)和低值组(29例)。我们研究了这两组之间的临床和预后差异。
纳入患者(83例男性和18例女性)的平均年龄为68.0岁。高值组和低值组的5年总生存率分别为88%和60%(<0.01)。此外,高值组和低值组的2年无复发生存率分别为71%和54%(=0.03)。
这是第一项证明术后第一天血清AT-III水平可作为HCC患者预后因素的研究。